Roche runs from Repare

After several setbacks for ATR inhibitors last year Roche has dealt the mechanism another blow, yesterday walking away from Repare Therapeutics’ camonsertib. Roche licensed the project for $125m up front in June 2022; even at the time monotherapy activity was nothing to write home about, but there had been hopes for PARP inhibitor combinations. However, these also did not impress, and Repare’s focus for camonsertib now appears to be in combo with its PKMYT1 inhibitor lunresertib. Still, data from the Mythic study, presented at last year’s Triple meeting, were tricky to interpret – Repare has homed in on a subgroup of patients with heavily pretreated gynaecologic cancers, so this could be a focus for future development. A spokesperson for Repare told ApexOnco that it would give more details of its plans once it has brought camonsertib back into the fold. Repare recently announced the first patient had been dosed with camonseritb in Roche's Tapistry platform trial, earning the smaller group a $40m milestone. The most advanced ATR inhibitor is AstraZeneca’s ceralasertib, with the phase 3 Latify study in post-immunotherapy NSCLC due to yield data in 2025; however, Astra last year discontinued the Monettte melanoma study owing to futility, so hopes cannot be high. 

Trials of camonsertib

Note: ORR figures include CA-125 responses. Source: OncologyPipeline.

This story has been updated to clarify the status of the Tapistry & Morpheus-Lung trials.